# Strand Therapeutics

Source: https://onco.cc/companies/strand-therapeutics/  
OnCo record `strand-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Strand makes programmable messenger RNA medicines that switch on only inside tumours. Its first drug is injected into a tumour and makes cells there produce an immune-boosting signal.

## Summary

Strand Therapeutics is a clinical-stage mRNA company. Its platform combines SignalPath lipid nanoparticles for delivery beyond the liver, SignalLock microRNA-sensing circuits that activate the RNA in target tissue and silence it elsewhere, and SignalScript self-replicating and circular RNA for potency and durability. Lead programme STX-001 is a lipid nanoparticle-encapsulated self-replicating mRNA encoding interleukin-12, given intratumourally in advanced solid tumours; the IND cleared in January 2024, the first patient was dosed in May 2024 and initial phase 1 results were presented at ASCO 2025, with the company reporting complete responses. STX-003, a systemic tumour programme using SignalLock, is planned to enter the clinic in 2026, and STX-005 is an in vivo CAR-T programme for autoimmune disease and blood cancers. Strand raised a USD 52 million Series A (2021), USD 45 million Series A1 (2022) and USD 153 million Series B (August 2025).

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Boston, MA
- Type: biotech
- Website: https://www.strandtx.com

## Notes

- Series B investors are not named on the fetched company page; the Business Wire release could not be fetched (blocked). HQ inferred from Boston Business Journal awards referenced on the site. Founding year not sourced.

## Sources

- Official website: https://www.strandtx.com
- News and articles (Series B and STX-001 data): https://www.strandtx.com/articles

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- trials: [Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab](https://onco.cc/trials/nct06249048/), [Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab](https://onco.cc/trials/nct07751042/)

---
JSON: https://onco.cc/api/v1/entities/strand-therapeutics.json